The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Publications

Akopyan K, Zafar R, Faruqi I

History Is the Key to Diagnosis: A Case of Nitrofurantoin-Induced Interstitial Lung Disease.

Cureus. 2024;16(3):e56097

Speirs TP, Tuffin N, Mundy-Baird F, Sakota H, Mulholland S, Westlake M, Lyon M, Medford AR, Sharp C, Darby M, Albur M, Keeley F, Burden H, Kenward C, Jonas E, Barratt S, Adamali HI

Long-term nitrofurantoin: an analysis of complication awareness, monitoring, and pulmonary injury cases.

BJGP open. 2021;5(6)

Tzilas V, Charokopos A, Kolilekas L, Manali E, Papiris S, Ryu JH, Bouros D

Presenting Features and Clinical Course of Chronic Nitrofurantoin-Induced Lung Toxicity.

Chest. 2022;161(3):748-752

Yetkin NA, Cerrah Demir N

Nitrofurantoin induced interstitial lung disease mimicking COVID-19 pneumonia: Case report and review of the literature.

Tuberkuloz ve toraks. 2021;69(1):121-124

Twohig P, Rivington J

Drug-Induced Interstitial Lung Disease from a Misdiagnosed Infection.

Microbiology insights. 2018;11:1178636118798371

Claussen K, Stocks E, Bhat D, Fish J, Rubin CD

How Common Are Pulmonary and Hepatic Adverse Effects in Older Adults Prescribed Nitrofurantoin?

Journal of the American Geriatrics Society. 2017;65(6):1316-1320

Mullerpattan JB, Dagaonkar RS, Shah HD, Udwadia ZF

Fatal nitrofurantoin lung.

The Journal of the Association of Physicians of India. 2013;61(10):758-60

Reynolds TD, Thomas J

Nitrofurantoin related pulmonary disease: a clinical reminder.

BMJ case reports. 2013;2013

Madani Y, Mann B

Nitrofurantoin-induced lung disease and prophylaxis of urinary tract infections.

Primary care respiratory journal : journal of the General Practice Airways Group. 2012;21(3):337-41

Weir M, Daly GJ

Lung toxicity and Nitrofurantoin: the tip of the iceberg?

QJM : monthly journal of the Association of Physicians. 2013;106(3):271-2

Hardak E, Berger G, Krivoy N, Solomonov A, Yigla M

Nitrofurantoin pulmonary toxicity: neglected threat.

Current drug safety. 2010;5(2):125-8

Mendez JL, Nadrous HF, Hartman TE, Ryu JH

Chronic nitrofurantoin-induced lung disease.

Mayo Clinic proceedings. 2005;80(10):1298-302

Willcox PA, Maze SS, Sandler M, Benatar SR

Pulmonary fibrosis following long-term nitrofurantoin therapy.

South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde. 1982;61(19):714-7

Sovijärvi AR, Lemola M, Stenius B, Idänpään-Heikkilä J

Nitrofurantoin-induced acute, subacute and chronic pulmonary reactions.

Scandinavian journal of respiratory diseases. 1977;58(1):41-50